527 related articles for article (PubMed ID: 26119086)
1. Mycobacterium tuberculosis virulence: insights and impact on vaccine development.
Delogu G; Provvedi R; Sali M; Manganelli R
Future Microbiol; 2015; 10(7):1177-94. PubMed ID: 26119086
[TBL] [Abstract][Full Text] [Related]
2. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
3. Current status of new tuberculosis vaccine in children.
Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
[TBL] [Abstract][Full Text] [Related]
4. Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines.
Mascart F; Locht C
Expert Rev Vaccines; 2015; 14(12):1573-85. PubMed ID: 26517361
[TBL] [Abstract][Full Text] [Related]
5. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
6. Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain.
Marcus SA; Steinberg H; Talaat AM
Vaccine; 2015 Oct; 33(42):5633-5639. PubMed ID: 26363381
[TBL] [Abstract][Full Text] [Related]
7. BCG-mediated protection against M. tuberculosis is sustained post-malaria infection independent of parasite virulence.
Tangie E; Walters A; Hsu NJ; Fisher M; Magez S; Jacobs M; Keeton R
Immunology; 2022 Feb; 165(2):219-233. PubMed ID: 34775598
[TBL] [Abstract][Full Text] [Related]
8. Development of a new tuberculosis vaccine: is there value in the mucosal approach?
Diogo GR; Reljic R
Immunotherapy; 2014; 6(9):1001-13. PubMed ID: 25341121
[TBL] [Abstract][Full Text] [Related]
9. Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death.
Aporta A; Arbues A; Aguilo JI; Monzon M; Badiola JJ; de Martino A; Ferrer N; Marinova D; Anel A; Martin C; Pardo J
PLoS One; 2012; 7(9):e45213. PubMed ID: 23028853
[TBL] [Abstract][Full Text] [Related]
10. Critical research concepts in tuberculosis vaccine development.
Delogu G; Manganelli R; Brennan MJ
Clin Microbiol Infect; 2014 May; 20 Suppl 5():59-65. PubMed ID: 24283256
[TBL] [Abstract][Full Text] [Related]
11. New tuberculosis vaccines.
Martín Montañés C; Gicquel B
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():57-62. PubMed ID: 21420568
[TBL] [Abstract][Full Text] [Related]
12. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis.
Waeckerle-Men Y; Bruffaerts N; Liang Y; Jurion F; Sander P; Kündig TM; Huygen K; Johansen P
Vaccine; 2013 Feb; 31(7):1057-64. PubMed ID: 23273509
[TBL] [Abstract][Full Text] [Related]
13. Advances in tuberculosis vaccine strategies.
Skeiky YA; Sadoff JC
Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
[TBL] [Abstract][Full Text] [Related]
14.
Ryndak MB; Laal S
Front Cell Infect Microbiol; 2019; 9():299. PubMed ID: 31497538
[TBL] [Abstract][Full Text] [Related]
15. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.
Billeskov R; Grandal MV; Poulsen C; Christensen JP; Winther N; Vingsbo-Lundberg C; Hoang TT; van Deurs B; Song YH; Aagaard C; Andersen P; Dietrich J
Eur J Immunol; 2010 May; 40(5):1342-54. PubMed ID: 20186878
[TBL] [Abstract][Full Text] [Related]
16. Profiling the host immune response to tuberculosis vaccines.
Fletcher HA
Vaccine; 2015 Sep; 33(40):5313-5. PubMed ID: 26241949
[TBL] [Abstract][Full Text] [Related]
17. Development of tuberculosis vaccines in clinical trials: Current status.
Méndez-Samperio P
Scand J Immunol; 2018 Oct; 88(4):e12710. PubMed ID: 30175850
[TBL] [Abstract][Full Text] [Related]
18. Novel vaccine candidates against Mycobacterium tuberculosis.
Khoshnood S; Heidary M; Haeili M; Drancourt M; Darban-Sarokhalil D; Nasiri MJ; Lohrasbi V
Int J Biol Macromol; 2018 Dec; 120(Pt A):180-188. PubMed ID: 30098365
[TBL] [Abstract][Full Text] [Related]
19. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
Dietrich J; Doherty TM
APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867
[TBL] [Abstract][Full Text] [Related]
20. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
